Skip to content
WorldBrand.AI

Janssen Biotech

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2012

    Risperdal promotion and kickback allegations

    U.S. authorities alleged that Johnson & Johnson and Janssen promoted Risperdal for an unapproved use in elderly patients despite safety concerns and provided improper payments or incentives connected with nursing-home pharmacy distribution. The wider matter involved federal and state proceedings and a provisional settlement reported at approximately $2.3 billion. The allegations and settlement concerned the broader Johnson & Johnson and Janssen organization, rather than an independently reported Janssen Biotech operation.

    Source